SCL Science (A246960) Stock Overview
Produces medical hemostatic agents using biomimetic technology. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
A246960 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
SCL Science Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,010.00 |
| 52 Week High | ₩3,250.00 |
| 52 Week Low | ₩1,389.00 |
| Beta | 0.47 |
| 1 Month Change | 18.03% |
| 3 Month Change | 12.23% |
| 1 Year Change | -19.60% |
| 3 Year Change | -8.32% |
| 5 Year Change | -41.31% |
| Change since IPO | -58.45% |
Recent News & Updates
Would SCL Science (KOSDAQ:246960) Be Better Off With Less Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Is SCL Science (KOSDAQ:246960) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Recent updates
Shareholder Returns
| A246960 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | 8.5% | -7.8% | -1.9% |
| 1Y | -19.6% | -17.4% | 96.4% |
Return vs Industry: A246960 underperformed the KR Medical Equipment industry which returned -17.4% over the past year.
Return vs Market: A246960 underperformed the KR Market which returned 96.4% over the past year.
Price Volatility
| A246960 volatility | |
|---|---|
| A246960 Average Weekly Movement | 8.8% |
| Medical Equipment Industry Average Movement | 9.2% |
| Market Average Movement | 9.8% |
| 10% most volatile stocks in KR Market | 17.6% |
| 10% least volatile stocks in KR Market | 5.1% |
Stable Share Price: A246960 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A246960's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 114 | Moon Lee | www.innotherapy.com |
SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products include BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal, which is used for specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields, such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasis and sealing products; STOP, a non-bleeding intravascular injection; Film that prevents leakage at intestinal and vascular anastomosis sites; InnoLOCK and InTro vascular interventional procedure items; and operates bio-logistics business. The company also engages in conducting clinical trial analysis services related to new drug development, in vitro diagnostic medical device performance evaluation, transportation of pharmaceuticals and clinical trial samples, etc. The company was formerly known as InnoTherapy, Inc. and changed its name to SCL Science Inc. in March 2024.
SCL Science Inc. Fundamentals Summary
| A246960 fundamental statistics | |
|---|---|
| Market cap | ₩69.22b |
| Earnings (TTM) | -₩3.17b |
| Revenue (TTM) | ₩27.40b |
Is A246960 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A246960 income statement (TTM) | |
|---|---|
| Revenue | ₩27.40b |
| Cost of Revenue | ₩22.36b |
| Gross Profit | ₩5.05b |
| Other Expenses | ₩8.21b |
| Earnings | -₩3.17b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -93.11 |
| Gross Margin | 18.41% |
| Net Profit Margin | -11.56% |
| Debt/Equity Ratio | 87.6% |
How did A246960 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/20 11:06 |
| End of Day Share Price | 2026/08/20 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SCL Science Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Seung Doo Na | SK Securities Co., Ltd. |